Cresco Labs: Cantor Lowers Price Target To $12.65

On September 3, Cresco Labs (CSE: CL) announced that they closed their acquisition of Cultivate, a vertically integrated Massachusetts operator that was acquired for $90 million, plus a potential $68 million earn-out. Cultivate currently operates roughly 42,000 square feet of active canopy with an additional 20,000 square feet of canopy available for build-out. The company has 3 open dispensaries.

Cresco Labs currently has 17 analysts covering the name with an average 12-month price target of $23.97, or a 104% upside. Out of the 17 analysts, 5 have strong buy ratings, 11 have buy ratings and 1 analyst has a hold rating. The street high sits at $34 from Stifel-GMP while the lowest comes in at $18.

Cantor Fitzgerald sent out a note last week updating their model, and with that lowering their 12-month price target to $12.65 from $13.50 while reiterating their overweight rating. On the Cultivate deal, Cantor says that they are factoring in an increase of $9 million in revenue since the deal closed earlier than expected.

Cantor says that the company has a strong presence in Illinois and Pennsylvania, with them being a #1 or #2 retailer/wholesaler in those states respectively, but according to Cantor’s channel checks, there is softness in the growth rate for Pennsylvania, California, and Illinois.

Cantor came to the price target by placing 15% on top of the MSO average 2022 EBITDA multiple. This 15% premium to the multiple has been applied for a multitude of reasons, with the biggest being “rec optionality in several states (NY and others), and a more established track record.”

In Illinois, recreational sales dropped 5% month over month, but are up 8% over the second quarter average. This is below the 24% average that the second quarter saw. In Pennslyvania, Headset data shows a 7% month over month drop, and in California, data shows a lower 2% month over month drop.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Mergers Set the Stage for Uranium’s Growth Cycle | Forum-Baselode Merger

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Recommended

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

Related News

Silvercorp Metals: Canaccord Genuity Initiates Coverage With C$12 Price Target

This morning, Canaccord Genuity’s analyst Dalton Baretto initiated coverage on Silvercorp Metals (TSX: SVM) (NYSE:...

Monday, September 14, 2020, 11:58:00 AM

Bragg Gaming: Canaccord Drops Target To $21 Due To Sector Tailwinds

On November 8th, Bragg Gaming (TSX: BRAG) reported their third quarter financial results. The company...

Tuesday, November 23, 2021, 10:24:00 AM

General Electric Analyst Consensus Estimates For Q1 2021

General Electric (NYSE: GE) will be reporting their first quarter financial results on April 27th...

Tuesday, April 27, 2021, 05:30:00 AM

Emerge Commerce Sees Canaccord Reiterate $1.20 Price Target

On November 29th, Emerge Commerce (TSXV: ECOM) announced its third quarter financial results. The company...

Thursday, December 2, 2021, 03:33:00 PM

Cybin: Eight Capital Initiates With $8.15 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes...

Saturday, September 18, 2021, 04:14:00 PM